
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina's clinical consumables revenue exhibited a mid-single-digit year-over-year increase, signaling a positive trend in the company's core business. The continued success of the MiSeq i100 Plus in attracting new-to-sequencing customers further underscores Illumina's growth potential within the sequencing market. Additionally, the company's increased non-GAAP diluted EPS guidance, now ranging from $4.45 to $4.55, reflects strong operational momentum and favorable funding conditions.
Bears say
Illumina's outlook appears negative primarily due to anticipated revenue declines, with projections indicating a decrease of 1.5-2.5% year-over-year for 3Q25, resulting in reported revenue guidance of approximately $1.06-1.07 billion. Additionally, the company is experiencing a significant contraction in its instruments segment, expecting a y/y revenue decline of 4-6% while only modest growth of 1-3% is expected in sequencing consumables, excluding China. The recent drop in NovaSeq X shipments compared to both the previous quarter and the same period in the prior year further underscores the challenges Illumina faces in maintaining sales momentum.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares